# Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

> **NCT04120883** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Michigan** · enrollment: 8 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** Hydroxychloroquine lower dose
- **DRUG:** Hydroxychloroquine higher dose

## Key facts

- **NCT ID:** NCT04120883
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-25
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Unable to recruit additional participants after multiple extensions to planned enrollment period.
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120883, "Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04120883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*